Diagnosis of Alzheimer’s disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

ABSTRACT This paper presents the consensus of the Scientific Department of Cognitive Neurology and Aging from the Brazilian Academy of Neurology on the diagnostic criteria for Alzheimer’s disease (AD) in Brazil. The authors conducted a literature review regarding clinical and research criteria for AD diagnosis and proposed protocols for use at primary, secondary, and tertiary care levels. Within this clinical scenario, the diagnostic criteria for typical and atypical AD are presented as well as clinical, cognitive, and functional assessment tools and complementary propaedeutics with laboratory and neuroimaging tests. The use of biomarkers is also discussed for both clinical diagnosis (in specific conditions) and research.

[1]  P. Scheltens,et al.  Research Criteria for the Behavioral Variant of Alzheimer Disease , 2021, JAMA neurology.

[2]  M. Yassuda,et al.  The Figure Memory Test: diagnosis of memory impairment in populations with heterogeneous educational background , 2021, Dementia & neuropsychologia.

[3]  C. Anderson,et al.  Systematic review of coexistent epileptic seizures and Alzheimer's disease: Incidence and prevalence , 2021, Journal of the American Geriatrics Society.

[4]  David T. Jones,et al.  New insights into atypical Alzheimer's disease in the era of biomarkers , 2021, The Lancet Neurology.

[5]  D. Malta,et al.  Dementias in Brazil: increasing burden in the 2000–2016 period. Estimates from the Global Burden of Disease Study 2016 , 2020, Arquivos de Neuro-Psiquiatria.

[6]  D. Galimberti,et al.  Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease , 2020, NeuroImage: Clinical.

[7]  M. Filippi,et al.  An update on magnetic resonance imaging markers in AD , 2020, Therapeutic advances in neurological disorders.

[8]  D. Rujescu,et al.  Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives , 2020, Frontiers in Psychiatry.

[9]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[10]  Peter R. Martin,et al.  Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. , 2020, Brain : a journal of neurology.

[11]  J. Santabárbara,et al.  Cholesterol and Alzheimer’s Disease Risk: A Meta-Meta-Analysis , 2020, Brain sciences.

[12]  David T. Jones,et al.  Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes , 2020, Brain communications.

[13]  Val J Lowe,et al.  Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. , 2020, JAMA neurology.

[14]  G. Frisoni,et al.  Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. , 2020, The Cochrane database of systematic reviews.

[15]  H. Matsuda,et al.  Neuroimaging of Alzheimer’s disease: focus on amyloid and tau PET , 2019, Japanese Journal of Radiology.

[16]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2019 , 2019, Alzheimer's & dementia.

[17]  A. Sinclair,et al.  Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype , 2019, Alzheimer's & Dementia.

[18]  Yanguo Xin,et al.  Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis , 2019, Neuroscience & Biobehavioral Reviews.

[19]  J. Clarimón,et al.  Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[20]  P. Lewczuk,et al.  Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease , 2019, Alzheimer's Research & Therapy.

[21]  M. Yassuda,et al.  Screening for Alzheimer's disease in low-educated or illiterate older adults in Brazil: a systematic review , 2018, Arquivos de Neuro-Psiquiatria.

[22]  K. Blennow,et al.  Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report , 2019, The Journal of Prevention of Alzheimer's Disease.

[23]  Jong Hun Kim.  Genetics of Alzheimer's Disease , 2018, Dementia and neurocognitive disorders.

[24]  I. Lacerda,et al.  Patterns of discrepancies in different objects of awareness in mild and moderate Alzheimer’s disease , 2018, Aging & mental health.

[25]  Sterling C. Johnson,et al.  Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia , 2018, Molecular Neurobiology.

[26]  M. Gorno-Tempini,et al.  Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review , 2018, Front. Neurol..

[27]  O. Forlenza,et al.  Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer’s disease patients , 2018, European Archives of Psychiatry and Clinical Neuroscience.

[28]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[29]  L. Mosconi,et al.  Clinical Application of APOE in Alzheimer’s Prevention: A Precision Medicine Approach , 2018, The Journal of Prevention of Alzheimer's Disease.

[30]  D. Salmon,et al.  Alzheimer’s Disease: Past, Present, and Future , 2017, Journal of the International Neuropsychological Society.

[31]  James G. Bollinger,et al.  Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.

[32]  K. Blennow.  A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood , 2017, Neurology and Therapy.

[33]  Henrik Zetterberg,et al.  Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.

[34]  Nick C. Fox,et al.  Consensus classification of posterior cortical atrophy , 2017, Alzheimer's & Dementia.

[35]  F. Hane,et al.  Recent Progress in Alzheimer’s Disease Research, Part 2: Genetics and Epidemiology , 2017, Journal of Alzheimer's disease : JAD.

[36]  A. Fagan,et al.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. , 2016, JAMA neurology.

[37]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[38]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[39]  R. Buckner,et al.  Polygenic risk of Alzheimer disease is associated with early- and late-life processes , 2016, Neurology.

[40]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[41]  R. M. Oliveira,et al.  Brazilian Normative Data on Letter and Category Fluency Tasks: Effects of Gender, Age, and Geopolitical Region , 2016, Front. Psychol..

[42]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[43]  S. Gauthier,et al.  Imaging Alzheimer's disease pathophysiology with PET , 2016, Dementia & neuropsychologia.

[44]  Sterling C. Johnson,et al.  Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation , 2015, Alzheimer's & dementia.

[45]  Irving E. Vega,et al.  Biomarkers for the Early Detection and Progression of Alzheimer’s Disease , 2016, Neurotherapeutics.

[46]  D. Castillo-Carranza,et al.  Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease , 2015, Front. Cell. Neurosci..

[47]  A. Perret‐Liaudet,et al.  Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease , 2015, Front. Neurol..

[48]  Dylan T Burnette,et al.  ER trapping reveals Golgi enzymes continually revisit the ER through a recycling pathway that controls Golgi organization , 2015, Proceedings of the National Academy of Sciences.

[49]  H. Zetterberg,et al.  Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia , 2015, Alzheimer's & dementia.

[50]  Frederik Barkhof,et al.  The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. , 2015, Brain : a journal of neurology.

[51]  R. Grassi‐Oliveira,et al.  Brazilian preliminary norms and investigation of age and education effects on the Modified Wisconsin Card Sorting Test, Stroop Color and Word test and Digit Span test in adults , 2015, Dementia & neuropsychologia.

[52]  Andrew J. Saykin,et al.  A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[53]  Henry Engler,et al.  Fluorodeoxyglucose PET in Neurology and Psychiatry. , 2014, PET clinics.

[54]  Michael W. Weiner,et al.  The future of blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[55]  D. Salmon,et al.  Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. , 2014, Journal of Alzheimer's disease : JAD.

[56]  K. Blennow,et al.  Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid , 2013, Acta Neuropathologica.

[57]  Henrik Zetterberg,et al.  Plasma tau levels in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[58]  E. Teng,et al.  Clinicopathologic differences among patients with behavioral variant frontotemporal dementia , 2013, Neurology.

[59]  M. Yassuda,et al.  Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment , 2013, International journal of geriatric psychiatry.

[60]  L. Nyberg,et al.  Genetic and Lifestyle Predictors of 15‐Year Longitudinal Change in Episodic Memory , 2012, Journal of the American Geriatrics Society.

[61]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[62]  Mike P. Wattjes,et al.  Visual assessment of posterior atrophy development of a MRI rating scale , 2011, European Radiology.

[63]  M. Brundel,et al.  Cerebral microinfarcts: A systematic review of neuropathological studies , 2011, Alzheimer's & Dementia.

[64]  Ricardo Nitrini,et al.  Criteria for the diagnosis of Alzheimer’s disease: Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology , 2011, Dementia & neuropsychologia.

[65]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[66]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[67]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[68]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[69]  C. Buchpiguel,et al.  Diagnosis of Alzheimer’s disease in Brazil: Supplementary exams , 2011, Dementia & neuropsychologia.

[70]  J T O'Brien,et al.  EFNS guidelines for the diagnosis and management of Alzheimer’s disease , 2010, European journal of neurology.

[71]  M. Yassuda,et al.  Can the CAMCOG be a good cognitive test for patients with Alzheimer's disease with low levels of education? , 2010, International Psychogeriatrics.

[72]  R. Nitrini,et al.  Functional Disability in Alzheimer Disease: A Validation Study of the Brazilian Version of the Disability Assessment for Dementia (DAD-Br) , 2010, Alzheimer disease and associated disorders.

[73]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[74]  M. Yassuda,et al.  Cross-cultural adaptation, reliability and validity of the DAFS-R in a sample of Brazilian older adults. , 2010, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[75]  M. P. Foss,et al.  REY COMPLEX FIGURES FOR THE ELDERLY , 2010 .

[76]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[77]  Henry Brodaty,et al.  Management of behavioral problems in Alzheimer's disease , 2010, International Psychogeriatrics.

[78]  W. M. van der Flier,et al.  Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. , 2009, Radiology.

[79]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[80]  R. Lourenço,et al.  [Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): cross-cultural adaptation for use in Brazil]. , 2009, Cadernos de saude publica.

[81]  D. Delis,et al.  Quantification of five neuropsychological approaches to defining mild cognitive impairment. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[82]  L. Mucke,et al.  Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.

[83]  M. Yassuda,et al.  CAMcog as a screening tool for diagnosis of mild cognitive impairment and dementia in a Brazilian clinical sample of moderate to high education , 2008, International journal of geriatric psychiatry.

[84]  Sid E O'Bryant,et al.  Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. , 2008, Archives of neurology.

[85]  O. Forlenza,et al.  Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[86]  L. Camacho,et al.  [Cross-cultural adaptation of the Independence in Activities of Daily Living Index (Katz Index)]. , 2008, Cadernos de saude publica.

[87]  Julie S. Snowden,et al.  Cognitive Phenotypes in Alzheimer's Disease and Genetic Risk , 2007, Cortex.

[88]  C. Bottino,et al.  The Bayer: Activities of Daily Living Scale (B-ADL) in the differentiation between mild to moderate dementia and normal aging. , 2007, Revista brasileira de psiquiatria.

[89]  L. Malloy-Diniz,et al.  The Rey Auditory-Verbal Learning Test: applicability for the Brazilian elderly population. , 2007, Revista brasileira de psiquiatria.

[90]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[91]  J. Kaye,et al.  Validity of the Clinical Dementia Rating Scale for the Detection and Staging of Dementia in Brazilian Patients , 2007, Alzheimer disease and associated disorders.

[92]  P. Caramelli,et al.  Brazilian adaptation of the Addenbrooke’s Cognitive Examination-Revised (ACE-R) , 2007, Dementia & neuropsychologia.

[93]  Ricardo Nitrini,et al.  Category Fluency as a Screening Test for Alzheimer Disease in Illiterate and Literate Patients , 2007, Alzheimer disease and associated disorders.

[94]  John R Hodges,et al.  The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.

[95]  C. Bottino,et al.  Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[96]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[97]  L. Mansur,et al.  [Boston Naming Test: performance of Brazilian population from São Paulo]. , 2006, Pro-fono : revista de atualizacao cientifica.

[98]  W. M. van der Flier,et al.  Epidemiology and risk factors of dementia , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[99]  B. Damasceno,et al.  [Diagnosis of Alzheimer's disease in Brazil: cognitive and functional evaluation. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology]. , 2005, Arquivos de neuro-psiquiatria.

[100]  J P Miller,et al.  The AD8 , 2005, Neurology.

[101]  A. Damasceno,et al.  [Validation of the Brazilian version of mini-test CASI-S]. , 2005, Arquivos de neuro-psiquiatria.

[102]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[103]  L. Mosconi,et al.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[104]  S. Weintraub,et al.  The Activities of Daily Living Questionnaire: A Validation Study in Patients with Dementia , 2004, Alzheimer disease and associated disorders.

[105]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[106]  Ricardo Nitrini,et al.  Brazilian version of the Mattis dementia rating scale: diagnosis of mild dementia in Alzheimer's disease. , 2003, Arquivos de neuro-psiquiatria.

[107]  K. Shulman,et al.  A population based study on the intra and inter‐rater reliability of the clock drawing test in Brazil: the Bambuí Health and Ageing Study , 2003, International journal of geriatric psychiatry.

[108]  Ricardo Nitrini,et al.  [Suggestions for utilization of the mini-mental state examination in Brazil]. , 2003, Arquivos de neuro-psiquiatria.

[109]  R. Nitrini,et al.  Epidemiologic Survey of Dementia in a Community-Dwelling Brazilian Population , 2002, Alzheimer disease and associated disorders.

[110]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[111]  P. Bertolucci,et al.  The cognitive subscale of the "Alzheimer's Disease Assessment Scale" in a Brazilian sample. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[112]  P. Bertolucci,et al.  Applicability of the CERAD neuropsychological battery to Brazilian elderly. , 2001, Arquivos de neuro-psiquiatria.

[113]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[114]  Michael E. Phelps,et al.  Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[115]  H. Lehfeld,et al.  The Bayer Activities of Daily Living Scale (B-ADL) , 1998, Dementia and Geriatric Cognitive Disorders.

[116]  E. Massad,et al.  [Neuropsychological tests of simple application for diagnosing dementia]. , 1994, Arquivos de neuro-psiquiatria.

[117]  Anthony F Jorm,et al.  The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms , 1989, Psychological Medicine.

[118]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[119]  F. Huppert,et al.  CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia , 1986, British Journal of Psychiatry.

[120]  Ivan Silver,et al.  The challenge of time: Clock‐drawing and cognitive function in the elderly , 1986 .

[121]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[122]  M. Albert,et al.  The clinical utility of the dementia rating scale for assessing Alzheimer patients. , 1984, Journal of chronic diseases.

[123]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[124]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[125]  T. Kurosaki,et al.  Measurement of functional activities in older adults in the community. , 1982, Journal of gerontology.

[126]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[127]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.